No relief for Katta in KIADB scam, wife's plea dismissed

January 29, 2016

Bengaluru, Jan 29: The High Court on Thursday dismissed a petition filed by former minister Katta Subramanya Naidu’s wife K Sowbhagya questioning the constitutional validity of some sections of the Prevention of Money Laundering Act, 2002, and subsequent amendments made to the law in 2005, 2009 and 2012.

kattasJustice Anand Byrareddy also dismissed her petition for quashing of an order issued by the Enforcement Directorate on September 25, 2012, pertaining to seizure of 141 documents related to the assets of Naidu’s family, Itasca Software Development Pvt Ltd and 23 others in connection with the multi-crore compensation scam in the Karnataka Industrial Areas Development Board (KIADB) land acquisition.

Sowbhagya had challenged several sections of the Act, contending that an accused can be tried under this law if they had harmed national security or were involved in terrorist activity.

As the petitioner and the family were not involved in any such activities, they must not be tried under the said Act and the High Court must quash the action taken by the directorate in seizing their property documents and transactions, she argued.

The bench in its order stated that the power of search, seize and arrest were important aspects of investigation and the matter related to economic offences was not unusual.

Similar procedures are followed with regard to the Customs Act, 1962, the Prevention of Food Adulteration Act, 1954, and the Railway Property (Unlawful Possession) Act, 1966.

As a Lokayukta enquiry is pending against the Naidu family, Katta’s wife also sought the court’s direction for a joint hearing.

Request rejected

But the bench rejected her prayer, saying the Lokayukta conducted the enquiry under a different law whereas the directorate was trying them under the Money Laundering Act, hence the two matters could not be heard together.

The bench dismissed the petitioner stating that it was not maintainable and the said sections of the Act were constitutionally valid.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com web desk
July 1,2020

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 15,2020

Bengaluru, Apr 15: Karnataka and five other states have their coronavirus antibody test kits stuck in China because of the country's new policy of getting clearance from their government before a company exports its products.

Singapore-based Sensing Self Ltd and China’s Wondfo are the only companies that have cleared Pune's National Institute of Virology (NIV)’s validation for rapid antibody test kit.

Dr CN Manjunath, Director, Jayadeva Institute of Cardiovascular Sciences and Research, and nodal officer for COVID-19 lab testing, Karnataka, said, "Inventory is ready in Hong Kong Airport. Karnataka's consignment is stuck with five other states' consignments: Kerala, Andhra Pradesh, Rajasthan, Gujarat, and Meghalaya. On April 1 or 3, China's policy changed saying any exports going out of China has to be certified by the Chinese government."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com news network
February 16,2020

Uppinangady, Feb 16: Eleven people were injured, when a private bus in which they were travelling, toppled near Kodikal on Sunday, police said.

According to Police, more than 20 people were travelling in the bus towards Puttur from Sakleshpur when the mishap took place.

All the inmates were on their way to attend a wedding.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.